Description
Rôles et compétences
Rôles et compétences
- Reflections and experiences of early career cancer nurses on cancer survivorship in Europe: A qualitative study.on 16 février 2026
European Journal of Oncology Nursing; 02/01/2026This study explores how early-career cancer nurses across Europe conceptualise and deliver survivorship care, a growing priority in oncology nursing. […]
Formation et apprentissage
- Symptom Management Guideline Implementation Among Nurses in Cancer-Specific Outpatient Settings: A Scoping Review of Barriers, Facilitators, and Implementation Strategies.on 10 Décembre 2025
Cancer Nursing; 01/01/2026Background: Oncology outpatients experience high levels of distressing cancer-related symptoms. Nurses can provide high-quality outpatient cancer symptom management […]
Spécialités cliniques
Oncologie médicale
- Leveraging Artificial Intelligence for Immune Checkpoint Inhibitor Safety: A Scoping Review of Current Applicationson 16 mars 2026
JCO Clin Cancer Inform. 2026 Mar;10:e2500323. doi: 10.1200/CCI-25-00323. Epub 2026 Mar 9.ABSTRACTPURPOSE: To systematically map how artificial intelligence (AI) is being applied to immune-related […]
Chirurgie oncologique
- The AMICO Clinic Approach to Integrative Oncology in Breast Cancer Care: Structure and Clinical Framework From a Southern Italian Hospitalon 16 mars 2026
Integr Cancer Ther. 2026 Jan-Dec;25:15347354251413227. doi: 10.1177/15347354251413227. Epub 2026 Feb 16.ABSTRACTWith increasing survival rates for breast cancer (BC)-91% at 5 years and 80% at 15 […]
Radio-oncologie
- Alternative splicing in cancer drug resistance: Mechanisms and therapeutic prospects (Review)on 5 Décembre 2025
Oncol Rep. 2026 Feb;55(2):31. doi: 10.3892/or.2025.9036. Epub 2025 Dec 5.ABSTRACTAlternative splicing (AS) is one of the principal mechanisms of post‑transcriptional regulation that confers […]
Traitements et interventions
Traitements non-pharmacologiques
- Non-Pharmacological Interventions for Cough in Patients With Lung Cancer: A Systematic Review and Meta-Analysison 16 mars 2026
J Clin Nurs. 2026 Mar 15. doi: 10.1111/jocn.70289. Online ahead of print.ABSTRACTBACKGROUND: Cough, a prevalent and debilitating symptom of lung cancer, remains poorly managed. Accumulating evidence […]
Approches complémentaires
- Oral Chinese herbal medicine in combination with opioids for treatment of cancer pain: A systematic review and meta-analysison 16 mars 2026
J Tradit Complement Med. 2025 Dec 11;16(1):121-130. doi: 10.1016/j.jtcme.2025.12.002. eCollection 2026 Jan.ABSTRACTBACKGROUND AND AIM: While oral Chinese herbal medicine (OCHM) is frequently used for […]
Réadaptation, physiothérapie et ergothérapie
- Innovative Exercise in Routine Cancer Care: Insights from Eight Years of Integrated Oncological Exercise Therapy (OTT).on 16 mars 2026
Sports Medicine - Open; 03/04/2026Background: The beneficial effects of exercise in cancer patients are increasingly understood, whereas the inclusion of structured oncological exercise as a standard […]
Éducation aux patients et littératie en santé
- Cultural and Linguistic Adaptation and Validation of a Nutrition Literacy Instrument for Use in People With Cancer in the United Kingdomon 16 mars 2026
J Hum Nutr Diet. 2026 Apr;39(2):e70218. doi: 10.1111/jhn.70218.ABSTRACTBACKGROUND: Nutrition literacy is a person's ability to gain, retain and use nutrition information to inform healthy lifestyle […]
Organisation des soins
Organisation et unités de soins
- Interventional Oncology Is an Evolving Subspecialty for Oncology Nurses.on 16 février 2026
ONS Voice; 02/03/2026Although usually offered in larger, comprehensive cancer centers, IO is expanding as new discoveries and applications emerge. Many oncology nurses could come in contact with […]
Trajectoires de soins
- Return to work for health professionals with breast cancer as health recipients: A systematized reviewon 16 mars 2026
Work. 2026 Feb 16:10519815251410109. doi: 10.1177/10519815251410109. Online ahead of print.ABSTRACTBackgroundHealth professionals are at increased breast cancer(BC) risk. Occupational factors are […]
Performance et indicateurs
- Educational intervention in advanced practice nursing for managing symptoms, toxicities, and quality of life in patients with lung canceron 16 février 2026
Enferm Clin (Engl Ed). 2026 Feb 12:502402. doi: 10.1016/j.enfcle.2026.502402. Online ahead of print.ABSTRACTOBJECTIVE: To evaluate the effectiveness of a proactive educational telephone intervention, […]
Amélioration de la qualité et meilleures pratiques
- Patient Advocate-Trainee Engagement in Oncology Education: Insights from a Short Pilot Surveyon 16 janvier 2026
J Cancer Educ. 2026 Jan 16. doi: 10.1007/s13187-025-02823-8. Online ahead of print.NO ABSTRACTPMID:41543684 | DOI:10.1007/s13187-025-02823-8
Innovation
- Evaluation of symptom-management medications for predicting short-term survival in advanced cancer patients with machine learningon 16 février 2026
Digit Health. 2026 Feb 3;12:20552076261419945. doi: 10.1177/20552076261419945. eCollection 2026 Jan-Dec.ABSTRACTOBJECTIVE: Estimating the diverse symptoms of patients with advanced cancer is helpful […]
Expériences des patients
Expériences des patients
- Patients’ experiences of dysphagia and rehabilitation care needs across the pre-, intra-, and post-radiotherapy phases for head and neck cancer: a qualitative study.on 16 mars 2026
Supportive Care in Cancer; 03/01/2026(AN 191797067); ISSN: 09414355CINAHL Complete
Participation des patients
- Support through experience: The contribution of patient partners in oncologyon 16 janvier 2026
Soins. 2026 Jan-Feb;71(902):61-64. doi: 10.1016/j.soin.2025.11.015. Epub 2025 Dec 19.ABSTRACTThis article presents qualitative research, conducted in partnership with patient-partners-researchers, […]
Résultats rapportés par les patients
- Adaptation of digital integration of PROMs and PREMs in oncology during implementation: a scoping reviewon 16 mars 2026
Support Care Cancer. 2026 Mar 13;34(4):316. doi: 10.1007/s00520-026-10509-0.ABSTRACTPURPOSE: Digital tools facilitate the timely collection of patient-reported outcome and experience measures […]
Survivance
- Safety and Feasibility of Long‐Term High‐Intensity Interval Training With and Without Peer Support in Cancer Survivors.on 16 mars 2026
Scandinavian Journal of Medicine & Science in Sports (John Wiley & Sons, Inc.); 02/01/2026Despite the benefits of physical activity and exercise, including high‐intensity interval training […]
Publications d'associations professionnelles
Canadian Association of Nurses in Oncology (CANO/ACIO)
- Therapeutic breakthroughs in oncology: Enhancing treatment and managementon 11 septembre 2025
Can Oncol Nurs J. 2025 Jul 1;35(4):590-605. doi: 10.5737/23688076354590. eCollection 2025.ABSTRACTRecent advancements in oncology have significantly transformed cancer treatment and care management, offering new hope to patients worldwide. This literature review examines key therapeutic breakthroughs, including targeted therapies, immunotherapies, personalized medicine, and innovative drug delivery systems. These cutting-edge interventions have enhanced patient outcomes, improving survival rates and quality of life, but they have also introduced complexities in managing emerging side effects, care coordination, and resource allocation. This review discusses the implications of these therapies on patient care, the ethical considerations they entail, the management of side effects, and the pivotal role of oncology nurses in administering and managing these treatments. By exploring the current landscape and future directions of oncology therapies, including areas such as cancer vaccines and precision medicine, this article provides a comprehensive understanding of how these innovations are shaping the future of cancer care.PMID:40873601 | PMC:PMC12379890 | DOI:10.5737/23688076354590
Oncology Nursing Society (ONS)
- Bridging the Gap: The Role of Shared Decision-Making in Addressing Racial and Ethnic Disparities in Prostate-Specific Antigen Screeningon 16 mars 2026
Oncol Nurs Forum. 2026 Feb 25;53(2):e26535281. doi: 10.1188/26.ONF.e26535281.ABSTRACTOBJECTIVES: To assess racial and ethnic differences in prostate-specific antigen (PSA) screening and shared decision-making (SDM) and examine whether SDM modifies screening rates by race and ethnicity.SAMPLE & SETTING: Data from the 2021-2023 Behavioral Risk Factor Surveillance System were analyzed, including 10,778 men aged 55-69 years eligible for PSA screening.METHODS & VARIABLES: Descriptive statistics and chi-square tests assessed racial and ethnic differences in PSA screening and estimated SDM (eSDM) use. Multiple logistic regression models evaluated the impact of eSDM on PSA screening rates, including an interaction term for race and ethnicity and eSDM.RESULTS: Among the sample, 46% reported undergoing PSA screening in the past year. eSDM was a significant predictor of PSA screening. After adjusting for eSDM and covariates, racial disparities in screening rates were no longer significant. Only Asian American men showed a significantly lower likelihood of screening following SDM exposure compared to White men.IMPLICATION FOR NURSING: SDM can reduce racial and ethnic disparities in PSA screening. In addition, factors like healthcare access significantly influence screening rates, requiring targeted investigation. The results call for further investigation to culturally optimize SDM.PMID:41812019 | DOI:10.1188/26.ONF.e26535281
American Society of Clinical Oncology (ASCO)
- Cancer Control in Refugee and Asylum Seeker Populations: A Scoping Reviewon 16 mars 2026
JCO Glob Oncol. 2026 Feb;12:e2500307. doi: 10.1200/GO-25-00307. Epub 2026 Feb 20.ABSTRACTPURPOSE: Displaced individuals face significant health care access challenges, particularly for noncommunicable diseases. For these individuals, cancer control remains a severely neglected aspect of health care. This scoping review aims to synthesize and evaluate the current state of knowledge on equity within the cancer care continuum for refugee and asylum seeker populations worldwide.METHODS: A systematic search of PubMed and Embase was conducted for peer-reviewed articles published between 2000 and 2024, focusing on refugee and asylum seeker populations and cancer. Eligible studies addressed at least one stage of the cancer care continuum (prevention, detection, diagnosis, treatment, end-of-life care or survivorship) and included perspectives or outcomes of patients, caregivers, or providers. Data were extracted and mapped by study setting, population, cancer continuum stage, and type of barriers or interventions identified.RESULTS: Of 372 screened articles, 111 met inclusion criteria. The majority of research focused on cancer prevention, detection, and diagnosis. Common themes included low cancer awareness, reduced screening uptake, delayed diagnoses, treatment interruptions, and poor survival outcomes. Financial, social, and systemic barriers such as cost, stigma, language barriers, and inconsistent policies were frequently reported. Effective interventions included culturally tailored education, refugee-specific health clinics, use of interpreters, sex-concordant providers, and community engagement.CONCLUSION: Refugees and asylum seekers face persistent and multifaceted inequities in cancer care, shaped by both individual and systemic factors. Although some high-performing models and interventions exist, large gaps remain in research and service delivery. The findings emphasize the urgent need for an integrated strategy that incorporates the comprehensive cancer care needs of refugees and asylum seekers into national and international health policies.PMID:41719506 | DOI:10.1200/GO-25-00307
National Comprehensive Cancer Network (NCCN)
- Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomyon 16 mars 2026
J Natl Compr Canc Netw. 2026 Feb;24(2):11-18. doi: 10.6004/jnccn.2025.7102.ABSTRACTBACKGROUND: Salvage radiotherapy (sRT) is the standard of care for biochemical recurrence of prostate cancer following radical prostatectomy (RP). In this context, prostate-specific membrane antigen (PSMA) PET/CT offers superior sensitivity and specificity for the detection of recurrent disease. We aimed to evaluate the impact of PSMA PET/CT-guided management on clinical outcomes following sRT.PATIENTS AND METHODS: We retrospectively screened 5 prospective PSMA PET/CT studies conducted between 2016 and 2021. Eligible patients underwent PSMA PET/CT for restaging at first biochemical recurrence after RP, received sRT, and had ≥24 months of follow-up. Progression-free survival (PFS), freedom from distant progression, and overall survival (OS) were calculated using the Kaplan-Meier method. Adjusted hazard ratios (aHRs) for PFS were derived using Cox proportional hazards regression, adjusting for age, pre-sRT prostate-specific antigen (PSA) level, use of androgen deprivation therapy (ADT), and receipt of whole-pelvis radiotherapy (WPRT).RESULTS: Of the total cohort, 113 patients met the inclusion criteria. Median follow-up was 59.4 months (IQR, 47.4-69.5). Median PSA was 0.4 ng/mL (IQR, 0.3-1.1), and the median time from RP was 19.9 months (IQR, 5.6-51.8). On PSMA PET/CT, 19 (16.8%) patients were staged as TrN0M0, 32 (28.3%) as N1M0, 16 (14.2%) as M1, and 46 (40.7%) as T0N0M0 (no visible disease). ADT was administered to 76 (67.3%) patients, and 63 (55.8%) patients received WPRT. Disease progression occurred in 57 (50.4%) patients. Median PFS was 49.2 months (95% CI, 24.1-74.3), and median freedom from distant progression was 76.4 months (95% CI, 62.9-89.9). The 5-year OS rate was 97.1% (95% CI, 94.1%-100%). Receipt of WPRT was significantly associated with improved PFS among patients staged as TrN0M0 (aHR, 0.12; P=.035), whereas ADT was significantly associated with improved PFS in patients staged as N1/M1 (aHR, 0.37; P=.024).CONCLUSIONS: In this 5-year follow-up study from an institution that was an early adopter of PSMA PET/CT, PSMA PET/CT-guided sRT was associated with favorable oncologic outcomes. Exploratory analyses suggest a potential benefit of WPRT following a positive PSMA PET/CT and of ADT in patients with N1/M1 disease.PMID:41698328 | DOI:10.6004/jnccn.2025.7102
European Society for Medical Oncology (ESMO)
- FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiencyon 16 mars 2026
Patients should be tested for genetic variants of DPYD prior to initiating treatment
Pour obtenir les documents
L’accès au texte intégral des documents est restreint au personnel et aux médecins du CHUM en fonction des abonnements de la bibliothèque. Certains documents sont en accès libre sur le web.
Si vous êtes branchés sur le réseau CHUM :
Cliquer sur les liens fournis pour chaque référence pour vérifier la disponibilité du texte intégral.
Pour les articles provenant de PubMed, cliquer préalablement sur le lien suivant pour afficher la disponibilité du document.
Si vous êtes dans un autre établissement et que vous n’arrivez pas à accéder au texte intégral d’un article à partir du lien donné, vérifier auprès de la bibliothèque de votre institution en donnant la référence complète du document.
|
Avis de non-responsabilité
Le contenu des veilles informationnelles ou stratégiques (ci-après appelée « Veilles ») est mis à votre disposition à titre informatif pour un usage personnel exclusif. Tout usage commercial du contenu des Veilles est strictement interdit. Tous les éléments, articles, rapports ou toute autre source d’information figurant dans les Veilles, vous sont fournis « tels quels », sans garantie d’aucune sorte. Eu égard aux propos tenus dans les articles et les rapports sélectionnés pour les Veilles, le CHUM n’offre aucune garantie notamment d’exhaustivité, de fiabilité, d’actualité et d’exactitude.Le CHUM ne pourra en aucun cas être tenu responsable envers quiconque de tout dommage quel qu’il soit, même ceux directs, encouru notamment des suites de toute réclamation, action ou poursuite découlant, même directement, de l’utilisation de ces Veilles.
Les Veilles contiennent des liens vers des sites Web créés et mis à jour par des tierces parties. Ces liens sont fournis pour la commodité des utilisateurs seulement. Le CHUM n’endosse et ne garantit, ni explicitement ni implicitement, l’exactitude ou l’intégralité ni du contenu de ces hyperliens ni des opinions qui y sont exprimées. Le CHUM n’assume aucune responsabilité à l’égard de ces sites Web externes.
Le CHUM prend tous les moyens raisonnables afin de respecter les droits de propriété intellectuelle afférents au contenu des Veilles et aux modalités du prêt entre bibliothèques, émises par l’Université de Montréal. Le contenu des Veilles, incluant la manière dont il est présenté, sont notamment protégés par la Loi sur le droit d’auteur (L.R.C. (1985), ch. C-42). Le CHUM ne donne aucune garantie et ne fait aucune déclaration à l’effet que le contenu de ces veilles n’enfreint aucun droit d’une autre personne ou entité. Le téléchargement, la reproduction en un seul exemplaire ou le tirage sur papier des Veilles ne sont autorisés qu’à des fins de sauvegarde et pour un usage privé et non commercial. Tout téléchargement, reproduction, édition, diffusion sur Internet, utilisation à des fins commerciales ou publiques, distribution, publication sur un autre site ou sur quelque autre forme ainsi que toute autre utilisation est strictement interdite, à moins d’être faite dans le respect des règles de propriété intellectuelle applicables. |


